Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Barrons.com5d agoneutral
Pfizer CEO Says Covid Is ‘Irrelevant.’ He’s Betting on Cancer and Weight-Loss Drugs.StockStory6d agoneutral
BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shiftsStockStory6d agoneutral
5 must-read analyst questions from Bristol-Myers Squibb’s Q3 earnings callBarrons.com9d agoneutral
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling StockMT Newswires9d agoneutral
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $63Investor's Business Daily60d agoneutral
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?The Wall Street Journal61d agoneutral
Novartis Trial Failure Serves as Cautionary Tale for Pharma M&AThe Wall Street Journal66d agoneutral
Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side EffectsThe Wall Street Journal69d agoneutral
Novartis Pauses Autoimmune Cell Therapy Studies After DeathsSimply Wall St.71d agoneutral
Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test ValueInsider Monkey73d agoneutral
New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst24/7 Wall St.80d agoneutral
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPOSimply Wall St.85d agoneutral
Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval Lands24/7 Wall St.90d agoneutral
Interest Rates Could Still Rise in September: 5 High-Yield Passive Income Stocks Will Benefit